Echelon granted patent for PI3-K assay

By Elaine Rigoli

Tampa, Fla., June 19 - Echelon Biosciences, Inc. announced the allowance in the United States of its patent application covering non-radioactive, competitive phosphatidylinositol 3-kinase (PI3-K) assays.

The company said this patent reinforces its leadership position in the phospholipids research space, is the first patent allowance of its kind and strengthens the oncology synergy within Echelon's parent company, AEterna Zentaris.

PI3-K is a key cellular enzyme and is often altered in diseases, leading to abnormal cell growth in cancer and pathological cellular response in inflammation. Considerable research is being done to determine its importance and potential as a target for therapeutic development.

Given its notice of allowance, Echelon said it expects this patent to issue in the United States in the next few months.

Echelon, of Salt Lake City, is a wholly owned subsidiary of AEterna Zentaris of Quebec City, Quebec, a global biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.